The device focuses on examining sonoporation-based drug delivery that involves ultrasound-based treatment with microbubbles.

The upcoming report from Abbott (ABT) is expected to reveal quarterly earnings of $1.25 per share, indicating an increase of 9.7% compared to the year-ago period. Analysts forecast revenues of $11.07 ...

Abbott Laboratories ABT is slated to report second-quarter 2025 results on July 17, before the opening bell. The company delivered adjusted earnings per share (EPS) of $1.09 in the last quarter, which ...

Abbott Laboratories ABT has been delivering consistent organic growth in the Established Pharmaceuticals Division (EPD) and Diabetes segments. However, the soft neuromodulation business is a ...

According to Abbott, people with movement disorders will travel over 150 miles on average to visit specialists in deep brain stimulation. "We are continuing to make these kinds of investments and ...

Abbott's Neuromodulation group has created an app called the NeuroSphere Virtual Clinic, which allows patients with chronic pain who use spinal cord or dorsal root ganglion stimulators to have ...

Global neuromodulation market is poised to grow by USD 5.2 billion during 2020-2024, progressing at a CAGR of more than 11%, ... Major Five Neuromodulation Market Companies: Abbott Laboratories.

Abbott’s neuromodulation medical director says the company’s spinal cord stimulator, which won gold at the 2025 Edison Awards, is small but mighty. By Elliott Davis Jr. | May 27, 2025.

The goal of the study, Abbott's vice president of neuromodulation, Pedro Malha, said in the release, "is to develop the clinical evidence necessary to determine whether DBS is a safe and effective ...